CVRx Is Maintained at Buy by Lake Street
CVRx Is Maintained at Buy by Lake
CVRx Price Target Cut to $12.00/Share From $18.00 by Lake Street
CVRx Price Target Cut to $12.00/Share From $18.00 by Lake
Lake Street Maintains Buy on CVRx, Lowers Price Target to $12
Lake Street analyst Frank Takkinen maintains CVRx (NASDAQ:CVRX) with a Buy and lowers the price target from $18 to $12.
CVRx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 37.93% Lake Street $18 → $12 Maintains Buy 05/01/2024 106.9% Lake Street $35 → $18 Maintains
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $12
Lake Street analyst Frank Takkinen maintains $CVRx Inc(CVRX.US)$ with a buy rating, and adjusts the target price from $18 to $12.According to TipRanks data, the analyst has a success rate of 38.0%
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $15
Craig-Hallum analyst Chase Knickerbocker maintains $CVRx Inc(CVRX.US)$ with a buy rating, and sets the target price at $15.According to TipRanks data, the analyst has a success rate of 45.5% and a
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $14
CCORF analyst William Plovanic maintains $CVRx Inc(CVRX.US)$ with a buy rating, and adjusts the target price from $32 to $14.According to TipRanks data, the analyst has a success rate of 41.5% and a
Express News | CVRx, Inc. : Craig-Hallum Cuts Target Price to $15 From $23
Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO) and CVRx (CVRX)
CVRx Plunges, Sight Sciences Jumps on Proposed Medicare Rate Changes
Express News | Watching Shares Of CVRx, Shares Move Lower As Traders Circulate Report That Canaccord Says CVRx Faces Significant Reimbursement Cut In CMS Proposal; Barostim Procedures' Reimbursement May Drop From $45K To $31,222 Next Year; Final Ruling Expected...
Another Abbott Exec Leaves for CVRx
CVRx: Chief Revenue Officer Effective June 27 >CVRX
CVRx: Chief Revenue Officer Effective June 27 >CVRX
Express News | CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer
12 Health Care Stocks Moving In Monday's After-Market Session
GainersASLAN Pharma (NASDAQ:ASLN) shares moved upwards by 11.9% to $0.4 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Biora Therapeutics (NASDA
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $CVRx Inc(CVRX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.5% and a total average return of 2.7% over the
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersENDRA Life Sciences (NASDAQ:NDRA) stock increased by 79.2% to $0.15 during Wednesday's regular session. The company's market cap stands at $1.6 million. Rezolute (NASDAQ:RZLT) stock moved upwar
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $18
Lake Street analyst Frank Takkinen maintains $CVRx Inc(CVRX.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 34.2% and a tota
Express News | CVRx Reiterated FY24 Outlook For Revenue At $50.0M-$53.0M Vs $50.8M Est., Gross Margin Of 83.0%-85.0%
Express News | CVRx Inc FY2024 Shr View $-2.50, Rev View $50.8 Mln -- LSEG IBES Data